ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.18
+2.91%Aug 12, 2026, 14:57 UTC
Acumen Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.
Source:Aug 12, 2026, 00:00 UTC
Acumen Pharmaceuticals reported a net loss of $32.7 million for Q2 2026, with research and development expenses of $27.8 million and cash and marketable securities of $110.2 million as of June 30, 2026.
Jun 17, 2026, 16:30 UTC
Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.
Jun 16, 2026, 11:30 UTC
Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.
Source: